Angiotensin-converting enzyme inhibitors in patients with Alport syndrome: can all patients benefit?

Research output: Contribution to journalComment/debatepeer-review

2 Scopus citations

Abstract

Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are prescribed to slow the progression of kidney disease in patients with Alport syndrome. In a recent publication by Yamamura et al. the authors showed an association of ACEi or ARB treatment with delay in ESKD, even for those patients with severe, truncating mutations. Despite these encouraging findings, there remain a number of clinical questions about the use of ACEi and ARBs in Alport syndrome.

Original languageEnglish (US)
Pages (from-to)1400-1402
Number of pages3
JournalKidney international
Volume98
Issue number6
DOIs
StatePublished - Dec 2020

Bibliographical note

Publisher Copyright:
© 2020 International Society of Nephrology

Fingerprint

Dive into the research topics of 'Angiotensin-converting enzyme inhibitors in patients with Alport syndrome: can all patients benefit?'. Together they form a unique fingerprint.

Cite this